Drugs that contain Sirolimus
1. Fyarro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8911786 | AADI | Nanoparticle comprising rapamycin and albumin as anticancer agent |
Feb, 2029
(4 years from now) | |
| US10206887 | AADI | Prion free nanoparticle compositions and methods of making thereof |
Apr, 2030
(5 years from now) | |
| US10705070 | AADI | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
Mar, 2036
(11 years from now) | |
| US10973806 | AADI | Methods of treating epithelioid cell tumors comprising administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin |
Jun, 2036
(12 years from now) | |
| US11497737 | AADI | Pharmaceutical compositions of albumin and rapamycin |
Oct, 2040
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 22, 2024 |
| Orphan Drug Exclusivity(ODE-386) | Nov 22, 2028 |
Market Authorisation Date: 22 November, 2021
Treatment: Treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma); Treatment of adult patients with locally advanced unresectable or m...
Dosage: POWDER;INTRAVENOUS
More Information on Dosage
FYARRO family patents
2. Rapamune patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5403833 (Pediatric) | PF PRISM CV | Methods of inhibiting transplant rejecton in mammals using rapamycin and derivatives and prodrugs thereof |
Oct, 2012
(11 years ago) | |
| US5100899 | PF PRISM CV | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
Jul, 2013
(10 years ago) | |
| US5536729 | PF PRISM CV | Rapamycin formulations for oral administration |
Sep, 2013
(10 years ago) | |
|
US5100899 (Pediatric) | PF PRISM CV | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
Jan, 2014
(10 years ago) | |
|
US5536729 (Pediatric) | PF PRISM CV | Rapamycin formulations for oral administration |
Mar, 2014
(10 years ago) | |
| US5989591 | PF PRISM CV | Rapamycin formulations for oral administration |
Mar, 2018
(6 years ago) | |
|
US5989591 (Pediatric) | PF PRISM CV | Rapamycin formulations for oral administration |
Sep, 2018
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | May 28, 2022 |
| Orphan Drug Exclusivity(ODE-92) | May 28, 2022 |
Market Authorisation Date: 25 January, 2010
Treatment: Inhibiting transplant rejection using rapamycin (sirolimus)
Dosage: TABLET;ORAL; SOLUTION;ORAL
How can I launch a generic of RAPAMUNE before it's drug patent expiration?
More Information on Dosage
RAPAMUNE family patents